Glycolipids are biomolecules containing one or more carbohydrate residues linked to a hydrophobic lipid moiety through a glycosidic linkage. Glycolipids containing either a sphingoid or a ceramide as the hydrophobic lipid moiety are referred to as glycosphingolipids. Glycosphingolipids possess highly heterogeneous and diverse molecular structures in their carbohydrate chains and the lipid moieties. Based on their basic carbohydrate structures, glycosphingolipids are classified into the following series, namely, ganglio-, isoganglio-, lacto-, neolacto-, lactoganglio-, globo-, isoglobo-, muco-, gala-, neogala-, mollu-, arthro-, schistoand spirometo-series Table 1 . Acidic glycosphingolipids containing one or more sialic acid N-acetylneuraminic acid or N-glycolylneuraminic acid residue s in their carbohydrate moiety are especially referred to as gangliosides. Figure 2 shows the structures and metabolic pathways of ganglio-series gangliosides. Ganglio-series glycosphingolipids having 0, 1, 2 and 3 sialic acid residue s linked to the inner galactose residue are classified into asialo-, a-, band c-series gangliosides, respectively. In addition, ganglio- Glycosphingolipids including these gangliosides are primarily synthesized in the endoplasmic reticulum and further modified in the Golgi apparatus by sequential addition of additional carbohydrate moieties 3 to an existing acceptor lipid molecule. The reaction is catalyzed by a series of specific glycosyltransferases. With the exception of GM4, which is derived from galactosylceramide GalCer , most gangliosides are synthesized from lactosylceramide LacCer . First, a simple ganglioside, GM3, is synthesized by addition of a sialic acid to LacCer by CMP-sialic acid: LacCer α2-3 sialyltransferase ST-I or GM3 synthase . GD3 and GT3 are synthesized by sequential addition of sialic acids to GM3 and GD3 by CMP-sialic acid: GM3 α2-8 sialyltransferase ST-II or GD3 synthase and CMP-sialic acid: GD3 α2-8 sialyltransferase ST-III or GT3 synthase , respectively. GM3, GD3 and GT3 further serve as precursors of more complex gangliosides belonging to the a-, b-and c-series, respectively. Elaboration of these simple gangliosides to complex gangliosides is catalyzed by UDP-GalNAc: LacCer/GM3/GD3/GT3 β1-4 N-acetylgalactosaminyltransferase GalNAcT or GA2/GM2/GD2/GT2 synthase ,
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Glycolipids are biomolecules containing one or more carbohydrate residues linked to a hydrophobic lipid moiety through a glycosidic linkage. Glycolipids containing either a sphingoid or a ceramide as the hydrophobic lipid moiety are referred to as glycosphingolipids. Glycosphingolipids possess highly heterogeneous and diverse molecular structures in their carbohydrate chains and the lipid moieties. Based on their basic carbohydrate structures, glycosphingolipids are classified into the following series, namely, ganglio-, isoganglio-, lacto-, neolacto-, lactoganglio-, globo-, isoglobo-, muco-, gala-, neogala-, mollu-, arthro-, schistoand spirometo-series Table 1 . Acidic glycosphingolipids containing one or more sialic acid N-acetylneuraminic acid or N-glycolylneuraminic acid residue s in their carbohydrate moiety are especially referred to as gangliosides. Figure 1 depicts a common brain ganglioside, GM1. As of 2004, 188 gangliosides have been identified in vertebrate tissues 1 . Figure 2 shows the structures and metabolic pathways of ganglio-series gangliosides. Ganglio-series glycosphingolipids having 0, 1, 2 and 3 sialic acid residue s linked to the inner galactose residue are classified into asialo-, a-, band c-series gangliosides, respectively. In addition, ganglio-UDP-Gal: GA2/GM2/GD2/GT2 β1-3 galactosyltransferase GalT-II or GA1/GM1/GD1b/GT1c synthase , CMP-sialic acid: GA1/GM1/GD1b/GT1c α2-3 sialyltransferase ST-IV or GM1b/GD1a/GT1b/GQ1c synthase , and CMP-sialic acid: GM1b/GD1a/GT1b/GQ1c α2-8 sialyltransferase ST-V or GD1α/GT1aα/GQ1bα/GP1cα . Asialo-series gangliosides are also synthesized from LacCer by these glycosyltransferases along a different pathway.
Interestingly, the expression levels and patterns of ganglio-series gangliosides undergo dramatic changes during brain development 4, 5 . For instance, in human and rodent embryonic brains, the predominant gangliosides are simple GM3 and GD3. As the brain develops, the expression of these simple gangliosides is down-regulated with concomitant up-regulation of complex gangliosides such as GM1, GD1a, GD1b and GT1b. This change in expression levels and patterns of gangliosides can be largely attributed to the developmental change of the expression levels and patterns of ganglioside synthases glycosyltransferases 6, 7 that are spatiotemporally regulated, both at the transcriptional and post-translational levels, by multiple systems, including transcription factors 7 and probably epigenetic modifications 8 .
Functions of gangliosides
Gangliosides are ubiquitously found in tissues and body fluids, and are more abundantly expressed in the nervous system 9 . In cells, gangliosides are primarily, but not exclusively, localized in the outer leaflets of plasma membranes. On the cell surface, gangliosides are involved in cell-cell recognition and adhesion and signal transduction within specific cell surface microdomains, termed caveolae 10 , lipid rafts 11 , or glycosphingolipid-enriched microdomains 12 ,
with other membrane components such as sphingomyelin and cholesterol. Evidence is accumulating that gangliosides are colocalized in the microdomain structures with signaling molecules and adhesion molecules. In addition to cell plasma membranes, gangliosides have been shown to be present on nuclear membranes, and they have recently been proposed to play important roles in modulating intracellular and intranuclear calcium homeostasis and the ensuing cellular functions 13 .
The biological importance of gangliosides has been revealed by analyses of genetically engineered mice deficient in ganglioside synthases Table 2 . In histological studies of ST-I knockout mice, selective degeneration of the organ of Corti sensory organ of hearing in the cochlea occurs, coincidently with the onset of hearing loss. The loss of GM3 in this mutant may contribute to complete deafness 14 . This observation implicates a role for GM3 ganglioside and its derivatives in the functional maturation of the cochlea during early development. Recently, it has been reported that the ST-I knockout mice exhibit a phenotype resembling attention-deficit hyperactivity disorder 15 , thus indicating a novel role of glycosphingolipids for maintaining neuropsychological balance. ST-II knockout mice, deficient in b-and c-series ganglio- Table 1 Carbohydrate structures of glycosphingolipids.
sides, exhibit intact nervous tissue morphology; however, the regenerative ability of injured hypoglossal nerve in these mice is found to be severely impaired 16 .
Mice lacking complex hexosamine-containing braintype gangliosides, such as GM1, GD1a, GD1b and GT1b, caused by GalNAcT gene disruption show apparently normal histogenesis of brain and gross behavior 17 , but impaired motor coordination in older animals 18 . Interestingly, the nerve conduction velocity is significantly lower in GalNAcT knockout mice than in the wild type, as demonstrated by analyses of evoked potentials of contralateral S1 somatosensory cortex after stimulating the peripheral tibial nerve at the Achilles tendon 17 , suggesting the involvement of complex gangliosides in neural functions, such as neuronal transmission, or in structural maintenance of the nervous system. The latter hypothesis has been supported by detailed morphological analyses with electron microscopy of the GalNAcT knockout mice: those animals revealed decreased myelination and axonal degeneration in sciatic nerves and demyelination in optic nerves 19, 20 , as well as neural degeneration, glial enlargement and synaptic remodeling in the dorsal horn of the spinal cord and dorsal root ganglia, especially in the sensory nerve system 20 .
When GalNAcT and ST-II genes are disrupted simultaneously, the double knockout mice express primarily GM3 with no brain-type gangliosides. These mice exhibit weight loss, progressive motor and sensory dysfunctions and deterioration in spatial learning and memory with aging 21, 22 . Additionally, the responses to treatment with oxotremorine, an agonist of muscarinic acetylcholine re-
Fig. 2
Structures and biosynthetic pathways of ganglio-series gangliosides. The nomenclature for gangliosides and the components are based on those of Svennerholm 53) and IUPAC-IUBMB Joint Commission on Biochemical Nomenclature 54) , respectively. Glycosyltransferases catalyzing the synthesis of glycosphingolipids, including gangliosides, are underlined. GD1α, GT1aα, GQ1bα, and GP1cα are classified as belonging to the α-series gangliosides.
ceptors mAChRs , are markedly attenuated, indicating the impairment of mAChR functions in the GM3-only mice 22 , while there is no clear causal association with any aforementioned neurological abnormalities. Likewise, substantial degeneration of Purkinji neurons has also been reported in the cerebellar cortex of the double knockout mice, which may possibly result from regional complement activation and inflammatory reactions, as shown by deposits of C1q complement in the cerebella 23 and a degeneration-rescuing effect by the crossbreed carrying the disrupted gene of C3 complement 24 .
A striking phenotype of high susceptibility to sound-induced seizures has been shown in another derived line of the double knockout mouse with a distinct genetic background, C57BL/6 25 . These ST-II/GalNAcT double knockout animals also display a shortened life span, typically with the death of 50 of the mice by 30 weeks of age.
Mice lacking all ganglioside expression resulting from knockout of both GalNAcT and ST-I genes suffer severe lethality. The majority of the double knockout mice die soon after weaning at 3 weeks 26 . The ganglioside-deficient mice reveal prominent vacuolization pathology in the cerebellar and spinal white matters, along with enhanced cell apoptosis, axonal degeneration and perturbed axon-glia interactions in the cerebral cortex under histopathological examinations 26 .
Despite the neurological abnormalities that have been observed in ganglioside synthase knockout mice, it remains to be elucidated whether those phenotypes result from functional deficiency of the particular ganglioside product s and/or from an acquired consequence of the anomalous accumulation of substrate precursors.
Gangliosides in stem cells
Gangliosides are gaining increasing attention recently in the field of stem cell biology. Stem cells are undifferentiated cells endowed with a high potential for proliferation and the capacity for self-renewal with retention of pluripotency or multipotency to differentiate into their progenies. Stem cells have attracted considerable attention in recent years because of their biological and clinical potentials for regenerative medicine. A number of unique ganglioside markers have been identified in stem cells 27, 28 . For instance, SSEA-4 a globo-series ganglioside having an NeuAcα2- (Viable)
Complete hearing loss 14) Degeneration of the sensory organ of hearing in cochlea 14) Attention-deficit hyperactivity disorder-like behavior 15) ST-II GM1, GD1a 16, 23, 25) (Viable) GM3, GD1a in embryo 16) Impaired regeneration of the lesioned hypoglossal nerve 16) GalNAcT GM3, GD3 17, 23, 25) (Viable)
Decreased myelination and axonal degeneration in CNS/PNS 19) Demyelination in PNS 19) Reduction in neural conduction velocity from the tibial nerve to the somatosensory cortex 17) Sensory nerve-dominant nerve degeneration and synaptic remodeling 20) Symptoms of Parkinson s disease: loss of dopaminergic neurons of the substantia nigra pars compacta, and aggregation of α-synuclein 55) ST-I/GalNAcT (ganglioside deficient) 26) (Viable; death soon after weaning) 26) Axonal degeneration and perturbed axon-glia interaction in CNS 26) ST-II/GalNAcT GM3 [23] [24] [25] (Viable; shortened life span) 25) Sudden death in response to lethal sound-induced seizures 25) Neurodegeneration by dysfunction of complement systems and inflamation 23, 24) GEM/raft transfiguration, complement activation, local inflammation 23, 24) Progressive dysfunction of motor coordination, marked deterioration in memory and learning 21, 22) Suppressed function of muscarinic type acetylcholine receptors 22) *In wildtype mice, the predominant gangliosides are GM3 and GD3 in embryonic brains and GM1, GD1a, GD1b and GT1b in adult brains.
Structures, Biosynthesis, and Functions of Gangliosides-an Overview
3Galβ1-3GalNAcβ1-R structure 29 is specifically expressed in human pluripotent embryonic stem cells 30 and induced pluripotent stem cells 31, 32 , GD3 is expressed in mouse and human mouse neural stem cells 33, 34 , and GD2 34, 35 and SSEA-4 36 are expressed in human mesenchymal stem cells.
Gangliosides are primarily localized on the cell surface. Thus, gangliosides can be used as specific cell surface marker molecules for identifying or isolating these stem cells 27, 28 .
Also, in brain cancer stem cells, a subpopulation of brain cancer cells has been reported. These cells exhibit stem cell-like characteristics, such as the ability for self-renewal and multipotency in addition to the capability to sustain brain tumor formation. These cells also express c-series gangliosides, also known as A2B5 antigens characteristic of embryonic cells 37, 38 . These gangliosides can be utilized not only as biomarkers for cancer stem cells, but also as targets for the treatment of brain tumors. Studies of stem cell gangliosides should prove to be a fertile area of research in the future.
Gangliosides and diseases
Gangliosides are involved in the pathology of many diseases. For example, Guillain-Barré syndrome, an acute polyradiculoneuropathy that leads to acute quadriplegia, is caused by an autoimmune response to cell surface gangliosides 39 . In influenza, a well known viral infectious disease, influenza A viruses recognize sialic acid residues of gangliosides and glycoproteins on cell surfaces as receptor molecules for invasion of host cells 40 . Lysosomal storage diseases such as GM1 gangliosidosis and GM2 gangliosidosis TaySachs disease and Sandhoff disease are caused by defects in the lysosomal glycosidases or specific co-activators, resulting in accumulation of the substrates, such as glycosphingolipids, including gangliosides. Human autosomal recessive infantile-onset symptomatic epilepsy syndrome, associated with developmental stagnation and blindness found in Old Order Amish pedigree, is caused by a nonsense mutation of ST-I GM3 synthase 41 . It has been recently suggested that GM3 in cell surface microdomains is involved in insulin resistance in type 2 diabetes, the most common metabolic disorder characterized by high blood glucose 42 .
In addition, the onset of Alzheimer s disease, the most common form of dementia and neurodegenerative disease, has been proposed to be initiated by aggregation of amyloid-β peptide caused by gangliosides 43, 44 . More recently, we found an increase of Chol-1α antigens, GQ1bα and GT1aα, which are specifically expressed in cholinergic neurons 45, 46 in the brain of Alzheimer s disease model transgenic mice 47 . The increase of Chol-1α gangliosides may present evidence for generation of cholinergic neurons and neurogenesis in Alzheimer s disease brains. Mounting evidence suggests that gangliosides modulate aggressive angiogenesis commonly found to support tumor growth. Seyfried and co-investigators 48 reported that GM3
and GD1a had an opposite effect on the responsiveness of human umbilical vein endothelial cells to vascular endothelial growth factor that promotes the endothelial cell survival, growth and migration. This is in concert with our earlier observation that GM3, a major endothelial cell ganglioside 49 , was a natural angiogenesis suppressor, but GD1a,
shed from the surface of certain tumor cells, could induce angiogenesis. This observation suggests that exogenously administered GM3 may have therapeutic potential for reducing angiogenesis for tumor suppression. These above reports suggest that gangliosides are important for prevention and treatment of certain diseases. In fact, there is a series of studies showing the neurotrophic effects of intracerebroventricularly administrated GM1, which is reported to improve the cognitive function in patients with Alzheimer s disease 50 .
Conclusion
It has been about 7 decades since Ernst Klenk, a German chemist and lipidologist 1896-1971 , first isolated gangliosides from the human brain 51, 52 . Early research in the ganglioside field was focused on structural analysis of these molecules. With the advent of modern methodologies, many novel structures were identified that form the basis for further studies into gaining a better understanding of their cellular and subcellular localization in various tissue sources. This was followed by extensive investigations of their biosynthetic pathways and the regulatory mechanisms of their metabolism. Many biosynthetic and catalytic enzymes responsible for their metabolism have been characterized and glycogenes coding for these enzymes cloned and studied. These efforts have formed a firm foundation for elucidating the biological functions of these molecules. Future research should be focused on their roles not only as structural components of biomembranes, but also their functions in cell-cell recognition and adhesion, and mediators in signal transduction.
